Pretreatment mortality risk prediction model in patients with polymyositis/dermatomyositis-associated interstitial lung disease.

Xianhua GuiWangzhong LiHanyi JiangRujia WangMin YuTingting ZhaoMiao MaJingjing DingZiyi JinYuying QiuXiaohua QiuYingwei ZhangMin CaoMei HuangMengshu CaoJinghong DaiHourong CaiXiaoyan XinYonglong Xiao

Published in: RMD open (2024)

We developed and validated an evidence-based mortality risk prediction model with simple, readily accessible clinical variables in patients with PM/DM-ILD, which may inform clinical decision-making.

Keyphrases

interstitial lung disease
systemic sclerosis
rheumatoid arthritis
idiopathic pulmonary fibrosis
decision making
air pollution
particulate matter
metabolic syndrome
type diabetes
adipose tissue
risk assessment
polycyclic aromatic hydrocarbons
weight loss